China Detains AstraZeneca (AZN) Staff in Data, Drug-import Probes - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN), PT $91.70, 'TL-01 final OS underwhelms', Shares down ~2.3%
September 9, 2024 3:07 PM EDTBofA Securities analyst Sachin Jain reiterated a Buy rating and $91.70 price target on AstraZeneca (NASDAQ: AZN).
The analyst comments "TL01 final OS underwhelming, puts TL01 approval at risk AZN presented final OS data for datopotamab from TL01 2L lung cancer study at World Lung,... More
AstraZeneca (AZN) Shares Down 3%+ Following Update
September 9, 2024 2:03 PM EDTAstraZeneca (NASDAQ: AZN) Shares Decline 3% Following Update.
At 2:50pm Eastern Time the company reported datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.
... More
AstraZeneca (AZN) Shares Down ~2.5% Following Update
September 9, 2024 1:58 PM EDTAstraZeneca (NASDAQ: AZN) Shares Down 2.5% Following Update.
At 2:50pm Eastern Time the company reported datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.
... More
